{"id":157358,"date":"2026-11-08T14:27:10","date_gmt":"2026-11-08T14:27:10","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/157358\/"},"modified":"2026-11-08T14:27:10","modified_gmt":"2026-11-08T14:27:10","slug":"novartis-experimental-heart-drug-fails-key-trial","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/157358\/","title":{"rendered":"Novartis Experimental Heart Drug Fails Key Trial"},"content":{"rendered":"<p>A trial of an experimental Novartis drug designed to reduce a genetic risk factor for heart disease has failed to demonstrate a reduction in deaths, heart attacks or strokes, raising questions about the effectiveness of the treatment approach.<\/p>\n<p>The drug, pelacarsen, was developed to lower levels of lipoprotein(a), commonly known as Lp(a), a blood particle linked to an increased risk of cardiovascular disease.<\/p>\n<p>Despite reducing Lp(a) levels by 78 per cent, the monthly treatment failed to prevent further heart attacks, reduce stroke risks or lower the need for emergency procedures to unblock clogged arteries.<\/p>\n<p>The findings followed a clinical trial involving more than 8,300 patients who had previously experienced major cardiovascular events. Participants received either a monthly 70-milligram dose of pelacarsen or a placebo and were monitored for a median period of 4.7 years.<\/p>\n<p>Dr Steven Nissen of the Cleveland Clinic, who presented the findings at the American Heart Association meeting in Chicago, said the outcome was unexpected.<\/p>\n<p>\u201cEverybody in the world, me included, thought that this was going to work,\u201d he said.<\/p>\n<p>Nissen described the results as completely neutral, noting that \u201cthe drug failed to demonstrate meaningful clinical benefits despite significantly lowering Lp(a) levels.\u201d\u00a0<\/p>\n<p>The study also found that 20.6 per cent of patients receiving pelacarsen discontinued treatment because of adverse effects, compared with 7.5 per cent among those given the placebo.<\/p>\n<p>Lp(a) is an inherited risk factor estimated to affect approximately 20 per cent of the global population. However, many people living with elevated levels are unaware of the condition.<\/p>\n<p>Researchers had hoped that reducing Lp(a) would produce benefits similar to those associated with statins, which lower LDL, commonly called bad cholesterol, and help reduce the risk of heart attacks and strokes.<\/p>\n<p>However, the findings have raised questions about whether lowering Lp(a) alone is sufficient to prevent cardiovascular complications.<\/p>\n<p>Experts have cautioned against abandoning Lp(a) as a potential treatment target, noting that \u201cfurther research involving different patient populations and treatment approaches is necessary.\u201d\u00a0<\/p>\n<p>Pelacarsen belongs to a class of medicines known as antisense oligonucleotides (ASOs), which work by reducing the production of proteins associated with faulty genes.<\/p>\n<p>Other pharmaceutical companies, including Amgen and Eli Lilly, are developing alternative experimental treatments targeting Lp(a) using small interfering RNA (siRNA) technology.<\/p>\n<p>Their drugs, olpasiran and lepodisiran, respectively, have demonstrated reductions in Lp(a) levels of approximately 95 per cent in earlier studies.<\/p>\n<p>Nissen, who is also involved in the lepodisiran trial, said \u201cdifferences in drug technology and patient populations could influence the outcomes of future studies.\u201d\u00a0<\/p>\n<p>He noted that the Amgen and Eli Lilly trials include more participants who have not previously experienced heart attacks or strokes, unlike the pelacarsen study.<\/p>\n<p>Results from Amgen\u2019s Phase 3 trial are expected in early 2028, while Eli Lilly\u2019s findings are anticipated in 2029.<\/p>\n<p>Separately, another cardiovascular trial presented at the American Heart Association meeting found that Novo Nordisk\u2019s experimental drug, ziltivekimab, failed to reduce major cardiovascular events despite successfully lowering inflammation.<\/p>\n<p>The drug was developed to neutralise interleukin-6, a key driver of inflammation associated with cardiovascular disease.<\/p>\n<p>The trial involved approximately 6,300 patients with heart disease, advanced kidney disease and systemic inflammation.<\/p>\n<p>Although the treatment reduced inflammation, it did not significantly lower the risk of death, heart attacks or strokes compared with a placebo.<\/p>\n<p>The findings followed Novo Nordisk\u2019s announcement in July that the trial had failed to demonstrate clinical benefits.<\/p>\n<p>The company subsequently discontinued two other late-stage trials involving ziltivekimab after an independent data monitoring committee concluded that they were unlikely to succeed.<\/p>\n<p>Dr Paul Ridker of Harvard\u2019s Brigham and Women\u2019s Hospital, who presented the findings, suggested that the patients\u2019 advanced disease could have limited the effectiveness of the anti-inflammatory treatment.<\/p>\n<p>Dr Priscilla Hsue of the University of California, Los Angeles, who was not involved in the study, also observed that inflammation might already have caused significant damage in the severely ill patients enrolled in the trial.<\/p>\n<p>Dr Donald Lloyd-Jones, a professor of cardiology at Boston University, said \u201cstudies involving different compounds and treatment strategies.*<\/p>\n<p>The two trials have renewed discussions among researchers about the relationship between cholesterol-related particles, inflammation and cardiovascular disease, as scientists continue searching for more effective ways to prevent heart-related deaths and complications.<\/p>\n","protected":false},"excerpt":{"rendered":"A trial of an experimental Novartis drug designed to reduce a genetic risk factor for heart disease has&hellip;\n","protected":false},"author":2,"featured_media":157359,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[4148,4396,23812,23695,206,73575],"class_list":["post-157358","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-attacks","tag-drug","tag-fails","tag-heart","tag-novartis","tag-prevent"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117581292753533273","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/157358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=157358"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/157358\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/157359"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=157358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=157358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=157358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}